BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/23/2022 2:39:01 PM | Browse: 372 | Download: 897
 |
Received |
|
2022-01-12 07:27 |
|
Peer-Review Started |
|
2022-01-12 07:28 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-03-16 03:17 |
|
Revised |
|
2022-03-18 06:13 |
|
Second Decision |
|
2022-05-23 03:28 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-05-28 07:12 |
|
Articles in Press |
|
2022-05-28 07:12 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-05-17 23:11 |
|
Typeset the Manuscript |
|
2022-05-30 07:40 |
|
Publish the Manuscript Online |
|
2022-06-23 14:39 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Kazuto Tajiri, Hiroyuki Ito, Kengo Kawai, Yoshiro Kashii, Yuka Hayashi, Aiko Murayama, Masami Minemura, Terumi Takahara, Yukihiro Shimizu and Ichiro Yasuda |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kazuto Tajiri, MD, PhD, Associate Professor, Department of Gastroenterology, Toyama University Hospital, 2630 Sugitani, Toyama 930-0194, Japan. tajikazu@med.u-toyama.ac.jp |
| Key Words |
Direct acting antivirals; Hepatitis C virus; Hepatocellular carcinoma; Recurrence; Liver fibrosis; Curative treatment |
| Core Tip |
To estimate the therapeutic value of direct-acting antivirals (DAA) in hepatitis C virus (HCV)-infected patients with a history of hepatocellular carcinoma (HCC), the clinical course of HCV patients with or without a history of HCC after DAA therapy was retrospectively analyzed. DAA treatment did not increase the incidence rate of HCC recurrence/occurrence or enhance malignant transformation of HCC in patients with a history of HCC. The risk of HCC recurrence after DAA therapy was significantly associated with the frequency of HCC recurrence/occurrence before DAA therapy. |
| Publish Date |
2022-06-23 14:39 |
| Citation |
Tajiri K, Ito H, Kawai K, Kashii Y, Hayashi Y, Murayama A, Minemura M, Takahara T, Shimizu Y, Yasuda I. Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma. World J Hepatol 2022; 14(6): 1190-1199 |
| URL |
https://www.wjgnet.com/1948-5182/full/v14/i6/1190.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v14.i6.1190 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
